Cyclodextrin diethyldithiocarbamate copper ii inclusion complexes: A promising chemotherapeutic delivery system against chemoresistant triple negative breast cancer cell lines
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractDiethyldithiocarbamate Copper II (DDC-Cu) has shown potent anticancer activity against a wide range of cancer cells, but further investigations are hindered by its practical insolubility in water. In this study, inclusion complexes of DDC-Cu with hydroxypropyl beta-cyclodextrin (HP) or sulfobutyl ether beta-cyclodextrin (SBE) were prepared and investigated as an approach to enhance the apparent solubility of DDC-Cu. Formulations were prepared by simple mixing of DDC-Cu with both cyclodextrin (CDs) at room temperature. Phase solubility assessments of the resulting solutions were performed. DDC-Cu CD solutions were freeze-dried for further characterisations by DSC, thermogravimetric analysis (TGA) and FT-IR. Stability and cytotoxicity studies were also performed to investigate the maintenance of DDC-Cu anticancer activity. The phase solubility profile deviated positively from the linearity (Ap type) showing significant solubility enhancement of the DDC-Cu in both CD solutions (approximately 4 mg/mL at 20% w/w CD solutions). The DSC and TGA analysis confirmed the solid solution status of DDC-Cu in CD. The resulting solutions of DDC-Cu were stable for 28 days and conveyed the anticancer activity of DDC-Cu on chemoresistant triple negative breast cancer cell lines, with IC50 values less than 200 nM. Overall, cyclodextrin DDC-Cu complexes offer a great potential for anticancer applications, as evidenced by their very positive effects against chemoresistant triple negative breast cancer cells.
CitationSaid Suliman A, Khoder M, Tolaymat I, Webster M, Alany RG, Wang W, Elhissi A, Najlah M. (2021) Cyclodextrin Diethyldithiocarbamate Copper II Inclusion Complexes: A Promising Chemotherapeutic Delivery System against Chemoresistant Triple Negative Breast Cancer Cell Lines. Pharmaceutics. 2021; 13(1):84. https://doi.org/10.3390/pharmaceutics13010084
PubMed ID33435151 (pubmed)
Description© 2021 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/pharmaceutics13010084
SponsorsThis research is funded by NPRP grant (NPRP9-337-3-069) from the Qatar National Research Fund (a member of Qatar Foundation).
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International
- Cyclodextrin Diethyldithiocarbamate Copper II Inclusion Complexes: A Promising Chemotherapeutic Delivery System against Chemoresistant Triple Negative Breast Cancer Cell Lines.
- Authors: Said Suliman A, Khoder M, Tolaymat I, Webster M, Alany RG, Wang W, Elhissi A, Najlah M
- Issue date: 2021 Jan 10
- Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers.
- Authors: Chen W, Yang W, Chen P, Huang Y, Li F
- Issue date: 2018 Dec 5
- Enhanced solubility of guanosine by inclusion complexes with cyclodextrin derivatives: Preparation, characterization, and evaluation.
- Authors: Mohandoss S, Atchudan R, Immanuel Edison TNJ, Mandal TK, Palanisamy S, You S, Napoleon AA, Shim JJ, Lee YR
- Issue date: 2019 Nov 15
- An ocular drug delivery system containing zinc diethyldithiocarbamate and HPbetaCD inclusion complex--corneal permeability, anti-cataract effects and mechanism studies.
- Authors: Wang S, Li D, Ito Y, Liu X, Zhang J, Wu C
- Issue date: 2004 Oct